CSL Behring Coronavirus Information

We are committed to continuing to provide our medicines to patients around the world, while pursuing COVID-19 treatments through a variety of collaborations.

Paul Perreault

COVID-19: A Message from Our CEO

"As the COVID-19 pandemic evolves, CSL remains committed to safeguarding our patients, our donors and our people. In keeping with our values-based culture, CSL has taken precautions to ensure our employees and our facilities remain safe so we can continue to deliver on our promise to patients and public health." - Paul Perreault, CEO & Managing Director, CSL Limited

Read Our Letter to Patients
CSL immunoglobulin manufacturing

Watch Online: CoVIg-19 Plasma Alliance Featured on NBC News

In the race to find a treatment for COVID-19, the use of antibody-rich plasma from those who have recovered from the novel coronavirus to treat patients who are suffering from the illness has emerged as a hopeful potential therapy. And CSL Behring is a key part of that effort.

Read More and Watch Video

News Releases & Updates

Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

26 MAY 2020: “The Fight Is In Us” Campaign Seeks to Mobilize COVID-19 Survivors to Accelerate the Development of Potentially Lifesaving Therapies

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration

7 MAY 2020: Rapidly expanding support for the Alliance is increasing donations of convalescent plasma to begin clinical production, while NIH collaboration confirms clinical trial approach

CSL Behring Australia Commences Development of Treatment for Serious Cases of COVID-19

6 MAY 2020: Plasma-derived therapeutic with potential to treat serious complications of COVID-19

COVID-19 Update

14 APRIL 2020: CSL continues to provide medicines to patients around the world.

 

CSL Behring’s Global Role in Battling COVID-19

14 APRIL 2020: Here is how CSL Behring is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19.

 

CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic

8 APRIL 2020: COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer.

 

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy

6 APRIL 2020: Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19.